Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$5.37
+4.9%
$6.43
$2.78
$8.85
$29.16M1.0329,875 shs2,607 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$0.74
+2.8%
$0.70
$0.38
$1.15
$26.89M0.4833,102 shs4,626 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.01
$0.02
$0.08
$2.14
$390K0.688.94 million shs8,190 shs
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$1.53
+1.3%
$1.50
$1.16
$6.24
$44.92M1.17214,777 shs32,303 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-3.55%-12.98%-15.69%-7.86%+31.64%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-1.91%+1.41%+2.80%+4.35%-32.71%
ObsEva SA stock logo
OBSV
ObsEva
+150.00%+1,150.00%-60.00%-85.71%-93.98%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
+4.48%-0.66%-11.40%+4.48%-28.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.3953 of 5 stars
3.55.00.00.02.23.30.6
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.2938 of 5 stars
3.35.00.00.02.22.51.3
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.7716 of 5 stars
3.53.00.04.12.50.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50188.64% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.50
Moderate Buy$2.75272.33% Upside
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
3.00
Buy$7.00357.52% Upside

Current Analyst Ratings

Latest RMTI, OBSV, FBRX, and APRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2024
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$2.75
3/27/2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$9.00 ➝ $11.00
3/26/2024
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/25/2024
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $9.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$580K50.27N/AN/A$4.54 per share1.18
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$0.97 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
$20.11M0.02N/AN/A$0.41 per share0.01
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
$83.61M0.54$0.02 per share74.70$0.75 per share2.04

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$14.29M-$3.99N/AN/AN/AN/A-65.58%-52.37%5/20/2024 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$31.48M-$1.04N/AN/AN/AN/A-94.27%-81.36%5/20/2024 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/A-416.36%-92.01%N/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$8.44M-$0.40N/A25.50N/A-10.09%-39.17%-13.87%5/14/2024 (Confirmed)

Latest RMTI, OBSV, FBRX, and APRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2024N/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.05N/A+$0.05N/AN/AN/A  
3/26/2024Q4 2023
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.56-$0.92-$0.36-$0.92$0.33 million$0.01 million
3/21/2024Q4 2023
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
-$0.08$0.02+$0.10$0.09$22.09 million$22.09 million
3/18/2024Q4 2023
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A-$0.04-$0.04-$0.04N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.13
5.13
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
10.45
10.45
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
0.46
1.73
1.38

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
ObsEva SA stock logo
OBSV
ObsEva
17.52%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
23.31%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
20.90%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
10.53%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
2.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.43 million4.30 millionNo Data
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
936.40 million32.56 millionOptionable
ObsEva SA stock logo
OBSV
ObsEva
4877.97 million66.74 millionNot Optionable
Rockwell Medical, Inc. stock logo
RMTI
Rockwell Medical
23729.36 million28.72 millionOptionable

RMTI, OBSV, FBRX, and APRE Headlines

SourceHeadline
Rockwell Medical, Inc. (RMTI)Rockwell Medical, Inc. (RMTI)
finance.yahoo.com - April 21 at 4:13 PM
Rockwell Medical Continues to Expand its Distribution Capabilities in Western United StatesRockwell Medical Continues to Expand its Distribution Capabilities in Western United States
finance.yahoo.com - April 17 at 7:50 AM
Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024
businesswire.com - April 16 at 6:00 AM
Rockwell Medical gains as global reach widensRockwell Medical gains as global reach widens
msn.com - April 4 at 5:50 PM
Rockwell Medical Expands Global Distribution in the Dominican Republic and BermudaRockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda
businesswire.com - April 4 at 6:00 AM
Rockwell Medical (RMTI) Increases Despite Market Slip: Heres What You Need to KnowRockwell Medical (RMTI) Increases Despite Market Slip: Here's What You Need to Know
zacks.com - March 26 at 7:21 PM
Rockwell Medical Full Year 2023 Earnings: EPS Beats ExpectationsRockwell Medical Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 26 at 5:55 PM
Q4 2024 EPS Estimates for Rockwell Medical, Inc. (NASDAQ:RMTI) Decreased by AnalystQ4 2024 EPS Estimates for Rockwell Medical, Inc. (NASDAQ:RMTI) Decreased by Analyst
marketbeat.com - March 26 at 7:54 AM
Rockwell Medical (NASDAQ:RMTI) Price Target Cut to $9.00Rockwell Medical (NASDAQ:RMTI) Price Target Cut to $9.00
marketbeat.com - March 25 at 8:21 AM
Rockwell Medical Named Great Place to Work for Second Year in a RowRockwell Medical Named 'Great Place to Work' for Second Year in a Row
businesswire.com - March 25 at 6:00 AM
Analysts Have Been Trimming Their Rockwell Medical, Inc. (NASDAQ:RMTI) Price Target After Its Latest ReportAnalysts Have Been Trimming Their Rockwell Medical, Inc. (NASDAQ:RMTI) Price Target After Its Latest Report
finance.yahoo.com - March 24 at 7:36 PM
Rockwell Medical, Inc. (RMTI) Q4 2023 Earnings Call TranscriptRockwell Medical, Inc. (RMTI) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 23 at 9:36 PM
Buy Rating Reaffirmed for Rockwell Med amidst Strategic Growth and Operational EfficiencyBuy Rating Reaffirmed for Rockwell Med amidst Strategic Growth and Operational Efficiency
markets.businessinsider.com - March 23 at 11:34 AM
Q4 2023 Rockwell Medical Inc Earnings CallQ4 2023 Rockwell Medical Inc Earnings Call
finance.yahoo.com - March 22 at 3:17 AM
Rockwell Medical: Q4 Earnings InsightsRockwell Medical: Q4 Earnings Insights
benzinga.com - March 21 at 11:32 AM
Rockwell Medical Shares Rise After Narrower 4Q Loss, Higher SalesRockwell Medical Shares Rise After Narrower 4Q Loss, Higher Sales
marketwatch.com - March 21 at 11:32 AM
RMTI Stock Earnings: Rockwell Medical Beats EPS, Misses Revenue for Q4 2023RMTI Stock Earnings: Rockwell Medical Beats EPS, Misses Revenue for Q4 2023
msn.com - March 21 at 11:32 AM
Rockwell Medical (RMTI) Q4 Earnings and Revenues Beat EstimatesRockwell Medical (RMTI) Q4 Earnings and Revenues Beat Estimates
zacks.com - March 21 at 8:11 AM
Rockwell Medical: Q4 Earnings SnapshotRockwell Medical: Q4 Earnings Snapshot
sfgate.com - March 21 at 6:32 AM
Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023
businesswire.com - March 21 at 6:00 AM
Rockwell Medical earnings preview: what Wall Street is expectingRockwell Medical earnings preview: what Wall Street is expecting
markets.businessinsider.com - March 20 at 3:29 PM
Rockwell Medical Inc Registered Shs hosts conference call for investorsRockwell Medical Inc Registered Shs hosts conference call for investors
markets.businessinsider.com - March 18 at 2:59 AM
Rockwell Automation names new chief information security officerRockwell Automation names new chief information security officer
biztimes.com - March 13 at 7:06 PM
Rockwell Medical (RMTI) Rises As Market Takes a Dip: Key FactsRockwell Medical (RMTI) Rises As Market Takes a Dip: Key Facts
zacks.com - March 11 at 7:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aprea Therapeutics logo

Aprea Therapeutics

NASDAQ:APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Forte Biosciences logo

Forte Biosciences

NASDAQ:FBRX
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
ObsEva logo

ObsEva

NASDAQ:OBSV
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Rockwell Medical logo

Rockwell Medical

NASDAQ:RMTI
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.